H1N1 Swine Flu Vaccine Market Review

Tuesday, May 11, 2010 General News J E 4
H1N1 Swine Flu Vaccine Market Review (Revenues Forecasts Lessons for Future Pandemic Vaccines) The H1N1 flu epidemic created a public health emergency in 2009. It also created an opportunity for vaccine manufacturers to demonstrate that working with governments of the US and countries around the world they could manufacture and distribute a vaccine for the virus strain that may have had an impact in reducing cases and deaths. ( ) Who were the companies that performed best in this market? How did goverment contracts play out? Most importantly what are lessons for future pandemic and high publicity vaccine products? It has looked at vaccine products over the past decade and has seen the rise of interest in these products among pharmaceutical companies. While many suggest the H1N1 was a one time event it believes there is something important to be gained in a market review of 2009 flu vaccine sales that will inform executives investors and market watchers who are interested in the vaccine market. This report takes a detailed look at the H1N1 vaccine sales of 2009 based on available annual reports. Companies covered include AstraZeneca Novartis Glaxo and CSL among others. As part of its coverage the report includes: * 2009 H1N1 Vaccine Sales Results * Stockpiles Returns Delivery Systems and other Issues and Trends in Vaccine Sales * H1N1 Etiology and Statistics * Forecasts for 2010-2013 Influenza Vaccine Market * Trending in Government Contracts * Seasonal and H1N1 Flu Market Interplay * Conclusions for Future Pandemic Vaccine Sales * Market Share of Major Companies * Company Profiles As part of its coverage the following vaccine makers are profiled * Baxter Healthcare * GlaxoSmithKline * CSL * Medimmune (Astra Zeneca) * Merck & Co. Inc * Novartis * Sanofi Pasteur * Sinovac * Hualan Biological Engineering Co. * Novovax To know more and to buy a copy of your report feel free to visit : Or Contact us at : Bharat Book Bureau Tel: +91 22 27578668 Fax: +91 22 27579131 Email: Website: Follow us on twitter:


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
JHP Pharmaceuticals Announces Successful Completio...
73% of Medical Practice Administrators Cite Rising...